Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. by �븳愿묓삊 et al.
© 2015 Lee et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
OncoTargets and Therapy 2015:8 347–356
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
347
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S75077
Use of transient elastography to predict de 
novo recurrence after radiofrequency ablation 
for hepatocellular carcinoma
sang hoon lee1
seung Up Kim1–3
Jeong Won Jang4
si hyun Bae4
sanghun lee1,3
Beom Kyung Kim1–3
Jun Yong Park1–3
Do Young Kim1–3
sang hoon ahn1–3
Kwang–hyub han1–3
1Department of internal Medicine, 
2institute of gastroenterology, Yonsei 
University college of Medicine, 3liver 
cirrhosis clinical research center, 
4Department of internal Medicine, 
college of Medicine, catholic 
University of Korea, seoul, Korea
Background/purpose: Liver stiffness (LS) measurement using transient elastography can 
accurately assess the degree of liver fibrosis, which is associated with the risk of the develop-
ment of hepatocellular carcinoma (HCC). We investigated whether LS values could predict 
HCC de novo recurrence after radiofrequency ablation (RFA).
Methods: This retrospective, multicenter study analyzed 111 patients with HCC who underwent 
RFA and LS measurement using transient elastography between May 2005 and April 2011. All 
patients were followed until March 2013 to monitor for HCC recurrence.
Results: This study included 76 men and 35 women with a mean age of 62.4 years, and the 
mean LS value was 21.2 kPa. During the follow-up period (median 22.4 months), 47 (42.3%) 
patients experienced HCC de novo recurrence, and 18 (16.2%) died. Patients with recurrence 
had significantly more frequent liver cirrhosis, more frequent history of previous treatment 
for HCC, higher total bilirubin, larger spleen size, larger total tumor size, higher tumor num-
ber, higher LS values, and lower platelet counts than those without recurrence (all P,0.05). 
On multivariate analysis, together with previous anti-HCC treatment history, patients with LS 
values .13.0 kPa were at significantly greater risk for recurrence after RFA, with a hazard 
ratio (HR) of 3.115 (95% confidence interval [CI], 1.238–7.842, P,0.05). Moreover, LS values 
independently predicted the mortality after RFA, with a HR of 9.834 (95% CI, 1.148–84.211, 
P,0.05), together with total bilirubin.
Conclusions: Our data suggest that LS measurement is a useful predictor of HCC de novo 
recurrence and overall survival after RFA.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide, 
and it is also a common cause of death in patients with chronic liver disease.1 The cura-
tive treatment options for HCC that are currently available are surgical resection, liver 
transplantation, and radiofrequency ablation (RFA).2 Among these options, RFA has 
been accepted as an effective nonsurgical curative treatment modality for early-stage 
HCC tumors (solitary tumors ,5 cm in diameter or fewer than three nodules ,3 cm in 
diameter.2,3 RFA achieves a satisfactory local response rate, with more than 80% com-
plete ablation in most studies.4 Several recent randomized controlled trials and repeated 
meta-analyses have shown that the rates of overall survival (OS) and recurrence-free 
survival after RFA are comparable with those after surgical therapy.4,5
Despite progressive improvements in the efficacy of RFA, the survival of patients 
with HCC who undergo RFA remains disappointing, mainly due to frequent intrahe-
patic recurrence of HCC after RFA.4 The cumulative recurrence rate 2–3 years after 
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RFA has been reported at 72%–80%.6,7 There are two types 
of intrahepatic recurrence of HCC after RFA: local tumor 
progression and de novo recurrence. Local tumor progres-
sion, known as local recurrence, results from direct dissemi-
nation of the original tumor along the peripheral margin of 
the ablated lesion, while de novo recurrence accounts for 
multicenter occurrence of a HCC tumor in a location remote 
from the ablated lesion.8 Local factors, which include tumor 
location, tumor numbers, direct invasion into vessels, and 
insufficient safety margins have been identified as significant 
predictors of local recurrence,6,7,9 whereas the necroinflam-
matory activity of hepatitis and the degree of liver fibrosis 
or cirrhosis have been shown to be significantly associated 
with de novo recurrence.10
The clinical role of transient elastography (TE) to mea-
sure liver stiffness (LS) has been widely investigated in 
assessment of the degree of liver fibrosis or identification 
of the presence of portal hypertension.11 In addition, several 
recent longitudinal studies proposed that TE can accurately 
predict HCC development in patients with chronic hepatitis 
B and C,12,13 and HCC recurrence after curative resection,14 
based on the significant correlation between the risk of HCC 
development and the degree of liver fibrosis.11
Therefore, in this study we investigated whether the 
degree of liver fibrosis assessed by performing TE could pre-
dict de novo recurrence in patients with HCC who received 
RFA with complete ablation.
Material and methods
Patients
Between May 2005 and April 2011, a total of 2,168 patients 
received RFA for HCC treatment. Of these, 139 patients 
with available LS values at least within 3 months (median 7 
[range, 0–78] days) prior to RFA were selected for the 
multicenter retrospective study. A further 28 patients 
were excluded based on our exclusion criteria (Figure 1). 
Especially because TE measures LS values at right hepatic 
lobe, patients with a history of right hepatectomy before 
enrollment were excluded. Finally, 111 patients (55 from 
Yonsei University and 56 from Catholic University) were 
included in the final statistical analysis. The study protocol 
conformed to the ethical guidelines of the 1975 Helsinki 
Declaration and was approved by the institutional review 
board of each institute.
Since this study was focused on whether TE could pre-
dict HCC de novo recurrence after RFA,15 15 patients who 
experienced local recurrence were excluded from the final 
analysis.
Diagnosis of hcc and liver cirrhosis
The diagnosis of HCC was based on dynamic imaging 
studies, biopsies, and alpha-fetoprotein (AFP) serology, 
according to the American Association for the Study of Liver 
Diseases guidelines.2 Before RFA, the size and number of 
HCC tumors were confirmed by performing imaging studies, 
including computed tomography (CT) or magnetic resonance 
imaging (MRI). The staging of HCC before RFA and recur-
rent HCC was assessed by using the Barcelona Clinic Liver 
Cancer (BCLC) staging system.16
If histologic information was not available, liver 
cirrhosis was clinically diagnosed as follows: (1) platelet 
count ,100,000/μL and ultrasonographic findings sugges-
tive of cirrhosis, including a blunted, nodular liver edge, 
accompanied by splenomegaly (.12 cm); (2) esophageal 
139 patients who underwent
RFA for HCC
134 subjects with
valid liver stiffness values
111 subjects were analyzed
1) Failure of liver stiffness measurement (n=2)
2) Invalid liver stiffness value (n=3)
1) Previous history of resection or LT (n=10)
2) Lost to follow up (n=6)
3) Combination of other curative therapy (n=6)
4) Other primary malignancy (n=1)
Figure 1 Flow diagram showing the process for selecting the study population.
Abbreviations: hcc, hepatocellular carcinoma; lT, liver transplantation; rFa, radiofrequency ablation.
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or gastric varices; or (3) overt complications of liver cir-
rhosis, including ascites, variceal bleeding, and hepatic 
encephalopathy.17
Data collection
Demographic, clinical, and laboratory data of the study popu-
lation were collected from electronic medical records and 
were reviewed retrospectively. At admission, 1 day before 
RFA, blood parameters, including platelet count, total biliru-
bin, serum albumin, creatinine, prothrombin time, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
AFP, and des-gamma carboxyl prothrombin (DCP) were 
recorded. Because aspartate-to-platelet ratio index (APRI) 
can be easily obtained at no additional cost, it was calculated 
on the day before RFA, and its ability to predict recurrence 
was compared with the predictive utility of TE.18
liver stiffness measurement
Only one experienced technician at each institute, who had 
performed at least 1,000 prior examinations and who was 
blind to the patients’ clinical data, was allowed to perform 
TE. The results were reported in kilopascals. The interquartile 
range (IQR) was defined as an index of intrinsic variability of 
LS values, corresponding to the interval of LS results contain-
ing 50% of the valid measurements between the 25th and 75th 
percentiles.19 The median value of successful measurements 
was selected to represent the LS value in a given patient. In 
this study, only LS examinations with at least ten validated 
measurements, an IQR-to-median ratio less than 0.3, and a 
success rate of at least 60% were considered reliable.14
radiofrequency ablation
RFA was performed either by an interventionist, percutane-
ously (n=107 [96.4%]), or by a surgeon, in an intraoperative 
setting (n=4 [3.6%]). Dynamic CT was routinely performed 
immediately after RFA, and a subsequent session of RFA 
was performed when the postprocedural CT revealed that the 
target lesion was not completely ablated. Procedure-related 
complications were also checked. Most patients (n=109 
[97.3%]) achieved complete ablation after one RFA session, 
whereas the others (n=2 [2.7%]) received two RFA sessions 
for complete ablation.
Follow up and recurrence
After discharge, patients underwent follow-up exams 1 month 
after RFA and every 3 months thereafter. Follow-up inves-
tigations included measurement of tumor markers (AFP and 
DCP) and imaging studies, including liver dynamic CT or 
MRI, for the detection of recurrence. The last follow-up date 
was March 31, 2013, and the median follow-up duration was 
22.4 (range, 1.1–77.3) months.
The de novo recurrence was defined as intrahepatic recur-
rence beyond the ablative margin, which was suggested to be 
the 0.5–1.0 cm – wide region that should ideally be ablated 
during RFA.8 The primary end point was recurrence-free 
survival, which was defined as the period between the date 
of RFA and the time of the first de novo recurrence detected 
by performing follow-up imaging studies, and the secondary 
end point was overall mortality.
statistical analysis
Data were expressed as the mean ± standard deviation (SD), 
median (range), or n (%), as appropriate. Variables were com-
pared by using the chi-square test (or Fisher’s exact test) for 
categorical data and Student’s t-test (or the Mann–Whitney 
U-test) for continuous variables. The cumulative incidence 
rates of recurrence were calculated by using the Kaplan–Meier 
method. To identify independent risk factors for recurrence, 
multivariate Cox proportional hazard regression analysis was 
performed, using the variables that were significant in the uni-
variate analysis. To prevent statistical error due to significant 
correlation between liver cirrhosis and LS values, multivari-
ate analysis used LS values for grading liver fibrosis. Hazard 
ratios (HR) and corresponding 95% confidence intervals (CI) 
also were indicated. A two-tailed P-value ,0.05 was consid-
ered to be statistically significant. The statistical analysis was 
performed with SPSS, version 18.0 (PASW Statistics Inc., 
Chicago, IL, USA).
Results
Baseline characteristics
The baseline characteristics of the 111 enrolled patients are sum-
marized in Table 1. The patient population consisted of 76 men 
and 35 women, with a mean age of 62.4 years. Hepatitis B 
virus (HBV) (n=71 [64.0%]) was the most common etiology of 
underlying liver disease. A total 75 (67.6%) patients had liver 
cirrhosis,13 and most of these (65 [86.7%]) patients had pre-
served liver function, of Child–Pugh class A. Among patients 
with HBV, 53 (74.6%) patients received antiviral therapy 
using nucleos(t)ide analogs according to a Korean guideline.20 
Among patients with Hepatitis C virus (HCV), three (15.8%) 
patients received antiviral treatment using pegylated interferon 
plus ribavirin before RFA. Of these, one patient experienced 
sustained virological response. Additionally, HCV eradication 
was achieved in two (10.5%) patients after RFA. However, 
the other (n=14 [73.7%]) patients with HCV could not receive 
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HCC (n=71 [64.0%]), 29.5 kPa in HCV-related HCC (n=19 
[17.1%]), and 21.6 kPa in Non-B and non-C (NBNC)-related 
HCC (n=21 [18.9%]) (P=0.009 by one-way analysis of vari-
ance ANOVA, and P=0.006 especially between HBV-related 
HCC and HCV-related HCC by Bonferroni method).
complication of rFa and clinical 
outcomes
Significant postprocedure complications occurred, including 
hepatic infarction (n=2), hepatic abscess (n=1), and biloma 
(n=1) (Table 2).21 All patients were managed appropriately, and 
none of the patients died of complications related to RFA.
Clinical outcomes of RFA are summarized in Table 2. 
The median follow-up duration was 22.4 (range, 1.1–77.3) 
months. During the study period, 47 (42.3%) patients expe-
rienced de novo recurrence, with a median time to recurrence 
of 14.9 (range, 2.5–36.1) months after RFA. Most de novo 
recurrence developed as BLCL stage B (n=41 [87.2%]). Dur-
ing the study period, 18 (16.2%) patients died, with a median 
time to overall mortality of 15.5 (range, 1.1–63.8) months.
comparison between patients with 
and without recurrence
When the characteristics of patients with and without recur-
rence were compared (Table 3), patients with recurrence had 
Table 1 Baseline characteristics of hcc patients (n=111)
Variables Values
Demographic variables
age, years 62.4±9.5
Male sex 76 (68.5)
Body mass index, kg/m2 24.5±3.2
etiology, hBV/hcV/nBnc 71 (64.0)/ 
19 (17.1)/21 (18.9)
anti-viral therapy in hBV/hcV 53 (74.6)/5 (26.3)
liver cirrhosis 75 (67.6)
child–Pugh class, a/B 65/10
Diabetes mellitus 34 (30.6)
Previous anti-hcc treatment history 55 (49.5)
rFa/Tace/others 7/47/1
laboratory variables
alanine aminotransferase, iU/l 35.6±21.5
aspartate aminotransferase, iU/l 45.5±30.5
serum albumin, mg/dl 3.83±0.57
Total bilirubin, mg/dl 0.87±0.43
Prothrombin time, inr 1.09±0.11
serum creatinine, mg/dl 0.89±0.27
Platelet count, 109/l 126±63
spleen size, cm 10.8±2.0
Tumor variables
alpha-fetoprotein, ng/ml 12.7 (0.8–3,100.0)
Des-gamma carboxy prothrombin, ng/ml 30.0 (2.2–2,000.0)
Tumor number
One/two/more than three 90 (81.1)/17  
(15.3)/4 (3.6)
Maximal tumor size, cm 2.0 (0.6–6.0)
Total tumor size, cm 2.1 (0.6–7.7)
Noninvasive fibrosis prediction tools
liver stiffness measurement
liver stiffness, kPa 21.2±14.1
interquartile range, kPa 2.8±2.6
interquartile range/median 0.13±0.07
success rate, % 96.3±0.1
Patients with liver stiffness $13 kPa 72 (64.9)
aPri 1.18±1.04
Notes: Variables are expressed as mean ± sD, median (range), n, or n (%).
Abbreviations: aPri, aspartate-to-platelet ratio index; hBV hepatitis B virus; 
hcc, hepatocellular carcinoma; hcV, hepatitis c virus; inr, international normal-
ized ratio; nBnc, non-B and non-c; rFa, radiofrequency ablation; sD, standard 
deviation; Tace, transcatheter arterial chemoembolization.
antiviral treatment due to advanced cirrhosis with pancytopenia, 
old age, or significant thyroid dysfunction.
A total of 55 patients (49.5%) had been treated previously 
by other noncurative modalities, including transcatheter arterial 
chemoembolization (TACE) (n=47), followed by RFA (n=7). 
The median maximal tumor size was 2.0 cm, and most tumors 
(n=90 [81.1%]) were detected as solitary masses. The mean LS 
value was 21.2 kPa (median 17.6 [range, 4.4–75.0] kPa) and the 
mean APRI was 1.18±1.04 (median 0.86 [range, 0.19–6.90]).
The mean LS value according to the etiology of HCC was 
significantly different in our study: 18.6 kPa in HBV-related 
Table 2 complications arising from radiofrequency ablation 
and clinical outcomes
Variables Values
Significant complication
hepatic infarction
hepatic abscess
2 (1.7)
1 (0.8)
Biloma 1 (0.8)
Median follow-up duration, months 22.4 (1.1–77.3)
De novo recurrence
Patients with de novo recurrence 47 (42.3)
Time to recurrence, months 14.9 (2.5–36.1)
recurrence type
De novo only/de novo and local recurrence 39/8
Bclc stage at recurrence
Bclc B/Bclc c without ehs/Bclc c with ehs 41/2/4
Mortality
Patients with mortality 18 (16.2)
Time to mortality, months 15.5 (1.1–63.8)
Main causes of mortality
hcc-related 6
hcc-unrelated
liver failure 5
shock (septic or hypovolemic) 3
Others 4
Notes: Variables are expressed as median (range), n, or n (%).
Abbreviations: Bclc, Barcelona clinic liver cancer; ehs, extrahepatic spread; 
hcc, hepatocellular carcinoma.
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significantly more frequent liver cirrhosis, more frequent 
history of previous treatment for HCC, higher total biliru-
bin, larger spleen size, larger total tumor size, higher tumor 
number, higher LS values, and significantly lower platelet 
counts than those without recurrence (all P,0.05). APRI 
score and tumor markers, including AFP and DCP, were not 
statistically different between the two groups (all P.0.05).
For a simplified and intuitive analysis, we adopted 13.0 kPa 
as the optimal LS cutoff value to stratify our study popula-
tion into high- and low-risk group for de novo recurrence.22 
This cutoff value was similar to the calculated cutoff value 
from our cohort to predict de novo recurrence (13.4 kPa; 
sensitivity, 87.2%; specificity, 54.7%).
Factors associated with recurrence
Univariate analysis found that a history of previous anti-
HCC treatments, total bilirubin, platelet count, spleen size, 
and LS values $13.0 kPa were significantly associated with 
recurrence (Table 4). A significant correlation was identi-
fied between clinically diagnosed cirrhosis and LS values 
(P,0.001 by Spearman correlation). Thus, clinically diag-
nosed cirrhosis was not incorporated into multivariate analy-
sis, to avoid the statistical redundancy with LS values, in spite 
of its statistical significance in univariate analysis (P=0.026). 
Subsequent multivariate analysis identified that together 
with a history of previous anti-HCC treatment, patients with 
LS values .13.0 kPa were at significantly greater risk for 
recurrence after RFA, with a HR of 3.115 (P,0.05; 95% CI, 
1.238–7.842) compared with those with LS values #13.0 kPa 
(Table 4). The cumulative incidence rate of recurrence was 
significantly higher in patients with LS values $13.0 kPa 
compared with those with LS values ,13.0 kPa (logrank 
test, P,0.001) (Figure 2). The cumulative incidence rates 
of recurrence at 1, 2, and 3 years were 33.4%, 64.9%, and 
Table 3 comparison of characteristics of patients with and without recurrence
Variables Patients with recurrence  
(n=47 [42.3%])
Patients without recurrence  
(n=64 [57.7%])
P-value
Demographic variables
age, years 63.4±8.2 61.6±10.4 ns
Male sex 35 (74.5) 41 (64.1) ns
Body mass index, kg/m2 24.0±2.5 24.9±3.6 ns
etiology, hBV/hcV/nBnc 24 (51.1)/12 (25.5)/11 (23.4) 47 (73.4)/7 (10.9)/10 (15.6) 0.080
antiviral therapy in hBV/hcV 19 (79.2)/3 (25.0) 34 (72.3)/2 (28.5) ns
liver cirrhosis 42 (89.4) 33 (51.6) ,0.001
Diabetes mellitus 16 (34.0) 18 (28.1) ns
Previous anti-hcc treatment history
rFa/Tace/Others
32 (68.1)
3/29/0
23 (35.9)
4/18/1
0.004
laboratory variables
alanine aminotransferase, iU/l 32.0±19.1 38.3±22.9 ns
serum albumin, mg/dl 3.76±0.51 3.87±0.61 ns
Total bilirubin, mg/dl 0.98±0.49 0.79±0.37 0.023
Prothrombin time, inr 1.08±0.11 1.09±0.11 ns
serum creatinine, mg/dl 0.88±0.22 0.90±0.30 ns
Platelet count, 109/l 104±33 142±75 0.002
spleen size, cm 11.6±2.1 10.3±1.8 0.001
Tumor variables
alpha-fetoprotein, ng/ml 118.9±281.5 187.1±532.4 ns
Des-gamma carboxyl prothrombin, ng/ml 187.7±427.7 80.8±254.2 ns
Multiple tumor
One/two/more than three 33 (70.2)/11 (23.4)/3 (6.4) 57 (89.0)/6 (9.4)/1 (1.6) 0.013
Maximal tumor size, cm 2.1±0.9 2.0±0.9 ns
Total tumor size, cm 2.7±1.4 2.2±1.0 0.041
Noninvasive fibrosis prediction tools
liver stiffness, kPa 25.8±14.3 17.8±13.1 0.003
Patients with liver stiffness $13 kPa 41 (87.2) 31 (48.4) ,0.001
aPri 1.23±0.76 1.15±1.22 ns
Notes: Variables are expressed as mean ± sD or n (%).
Abbreviations: aPri, aspartate-to-platelet ratio index; hBV, hepatitis B virus; hcc, hepatocellular carcinoma; hcV, hepatitis c virus; inr, international normalized ratio; 
NBNC, non-B and non-C; NS, not significant; RFA, radiofrequency ablation; SD, standard deviation; TACE, transcatheter arterial chemoembolization.
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70.7%, respectively, in patients with LS values $13.0 kPa, 
whereas they were 5.8%, 17.4%, and 24.9%, respectively, 
in patients with LS values ,13.0 kPa.
Approximately 25% of patients experienced recurrence 
despite having LS values ,13.0 kPa, so a cutoff value that 
could identify low-risk patients was also calculated and found 
to be 9.6 kPa. The cumulative incidence rates of recurrence at 
1, 2, and 3 years were 0%, 8.3%, and 8.3%, respectively, in 
patients with LS values ,9.6 kPa. In addition, among patients 
with HBV-related HCC (n=71), recurrence was not signifi-
cantly correlated with HBV DNA level (P=0.278) or anti-viral 
treatment (P=0.867). Similarly, recurrence was not correlated 
with HCV RNA level (P=0.552), antiviral treatment for HCV 
(P=0.129), or the achievement of sustained virological response 
(P=0.483) among patients with HCV-related HCC (n=19).
Factors associated with Os
On univariate analysis, total bilirubin, spleen size, and LS 
value .13.0 kPa significantly predicted OS after RFA 
Table 4 Predictors of recurrence and overall survival after radiofrequency ablation
Variables Recurrence Overall survival
Univariate Multivariate Univariate Multivariate
P-value P-value HR (95% CI) P-value P-value HR (95% CI)
Demographic variables
age, years ns 0.054
Male sex ns ns
Body mass index, kg/m2 ns ns
etiology, hBV/hcV/nBnc 0.093 ns
antiviral therapy in hBV/hcV ns ns
Diabetes mellitus ns ns
Previous anti-hcc treatment history 0.001 0.016 3.115 (1.238–7.842) ns
laboratory variables
alanine aminotransferase, iU/l ns
serum albumin, mg/dl ns ns
Total bilirubin, mg/dl 0.029 0.169 2.167 (0.719–6.529) 0.002 0.009 5.200 (1.508–17.930)
Prothrombin time, inr ns ns
serum creatinine, mg/dl ns ns
Platelet count, /μl 0.003 0.190 1.000 (1.000–1.000) ns
spleen size, cm 0.001 0.329 1.134 (0.881–1.461) 0.021 0.597 1.081 (0.809–1.446)
Tumor variables –
alpha-fetoprotein, ng/ml ns – ns
Des-gamma carboxyl prothrombin, ng/ml ns 0.075
Tumor number 0.049 0.155 1.900 (0.785–4.598) ns
Maximal tumor size, cm ns ns
Total tumor size, cm 0.054 ns
Noninvasive fibrosis prediction tools
liver stiffness $13 kPa ,0.001 0.016 3.115 (1.238–7.842) 0.019 0.037 9.834 (1.148–84.211)
aPri ns ns
Abbreviations: APRI, aspartate-to-platelet ratio index; CI, confidence interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NBNC, 
non-B and non-C; HR, hazard ratio; INR, international normalized ratio; NS, not significant.
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Figure 2 cumulative incidence rates of hcc recurrence after rFa based on 
stratified LS values (Kaplan–Meir plot).
Notes: The cumulative incidence rates of recurrence increased significantly in patients 
with ls $13 kPa compared to those with ls ,13 kPa (logrank test, P,0.001).
Abbreviations: hcc, hepatocellular carcinoma; ls, liver stiffness; rFa, radiofre-
quency ablation.
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(all P,0.05) (Table 4). Of these, LS values independently 
predicted OS after RFA, with a HR of 9.834 (P,0.05; 95% CI, 
1.148–84.211), together with total bilirubin level (Table 4). 
The cumulative incidence rate of mortality was significantly 
higher in patients with LS values $13.0 kPa than in those with 
LS values ,13.0 kPa (logrank test, P=0.002) (Figure 3). The 
cumulative incidence rates of mortality at 1, 2, and 3 years 
were 4.2%, 18.1%, and 33.3%, respectively, in patients 
with LS values $13.0 kPa, whereas no patients with 
LS values ,13.0 kPa died during this period.
Discussion
In this multicenter study, we found that LS values measured 
by using TE were a significant predictor of HCC de novo 
recurrence and OS after RFA. To prevent potential confound-
ing influences, we excluded patients who experienced only 
local tumor progression after RFA, which is associated with 
residual tumor cells and microscopic spread beyond the abla-
tion margin.8 Although this study design allowed us to reveal 
the association between the risk of HCC de novo recurrence 
and the degree of liver fibrosis assessed by using TE, our 
results should be interpreted with caution because we cannot 
know at the time of RFA which patients will experience local 
recurrence. However, when we included the patients who 
experienced only local tumor recurrence after RFA during 
the same study period (n=19) and redefined our primary end 
point as overall recurrence, this time including both local and 
de novo recurrence, the independent prognostic value of TE 
was maintained, though there was attenuated statistical power 
(HR, 3.443–2.112 for overall recurrence; HR, 9.834–4.232 
for overall mortality). Thus, further studies in a prospective 
setting that include all consecutive patients undergoing RFA 
are warranted to validate our results.
In our study, almost half of the patients (n=55 [49.5%]) 
had a previous history of local treatment, such as TACE or 
RFA, and previous anti-HCC treatment history was identified 
as an independent predictor of de novo recurrence, together 
with LS values. The exact mechanism is not clear, but this can 
be explained, in part, by altered tumor biology due to previous 
repeated local treatment, which can influence recurrence.23 
There are other well-known risk factors for de novo recurrence 
after RFA that represent tumor burden or underlying liver 
function. These factors include AFP level,15,24,25 tumor size,24 
multiplicity,25,26 presence of hepatitis,24 platelet counts,26 and 
serum albumin.26 However, these did not independently influ-
ence the risk of de novo recurrence in our study. This result 
might indicate that TE measures the degree of liver fibrosis, 
which is more closely related to the underlying liver function, 
leading to more sensitive predictions than the conventional 
parameters, such as platelet count, serum albumin level, 
or spleen size. Furthermore, although it has been recently 
proposed that some noninvasive fibrosis prediction indexes 
can predict recurrence after RFA,15 TE performed better 
than the well-known noninvasive fibrosis prediction index 
of APRI in our study. To prevent the confounding influence 
of underlying liver function, we proceeded with subgroup 
analysis for selected patients with Child–Pugh class A and 
found that LS values (P=0.029) and history of previous 
antitumor treatment (P=0.018) were also independently 
associated with the risk of de novo recurrence in multivari-
ate analysis. However, because the sample size of our study 
was relatively small and the tumor burden of our study 
participants was relatively low (median AFP, 12.7 ng/mL; 
81.1% had a single tumor; and median maximal tumor 
size was 2.0 cm), the attenuated prognostic significance of 
variables related to tumor burden should be reanalyzed in a 
future prospective study with a large sample size and wide 
range of tumor burdens.
We adopted a LS cutoff value of 13.0 kPa to deter-
mine cirrhotic range of LS values and high-risk group for 
recurrence.22 In addition, previous study concluded that 
chronic hepatitis B patients with LS values .13 kPa had a 
significantly higher risk of HCC development. Also, HCC 
patients with preoperative LS values .13.4 kPa experienced 
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Figure 3 Overall mortality rates after RFA based on stratified LS values (Kaplan–
Meir plot).
Notes: The cumulative incidence rates of mortality was significantly higher in patients 
with ls $13 kPa compared to those with ls ,13 kPa (logrank test, P=0.002).
Abbreviations: hcc, hepatocellular carcinoma; ls, liver stiffness; rFa, radiofre-
quency ablation.
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a higher incidence of HCC recurrence after curative resection 
than did their counterparts.14 Taken together, this indicates 
that 13 kPa might be a key cutoff, in various clinical settings, 
to stratify the different spectra of prognosis in patients with 
chronic liver disease, especially in terms of assessing the risk 
of HCC development. However, among the patients with LS 
values ,13 kPa, a significant proportion of patients were still 
at a relatively high risk of HCC recurrence after RFA. Indeed, 
approximately 25% of patients experienced recurrence at 
3 years after RFA despite having LS values ,13.0 kPa. 
Thus, we calculated a second cutoff value with a high negative 
predictive value (94.4%) and found that 9.6 kPa (positive pre-
dictive value, 49.4%; sensitivity, 97.9%; specificity, 26.6%) 
was a cutoff value that could identify a subpopulation with a 
low risk of HCC recurrence. The cumulative incidence rate at 
3 years was only 8.3% in patients with LS values ,9.6 kPa. 
The finding that LS values below the cirrhotic range (13 kPa) 
can also be associated with the risk of HCC development is 
supported by a previous study13 that reported that patients 
with LS values below the cirrhotic range (8–13 kPa) had a 
3.07-fold increased risk of HCC development compared with 
those with LS values ,8 kPa. However, the use of 9.6 kPa as 
a cutoff value in clinical practice still needs validation.
Because of the strong correlation between clinically 
diagnosed liver cirrhosis and LS values in our study 
(P,0.001 by Spearmen correlation), we included LS values 
in multivariate analysis instead of liver cirrhosis to prevent 
the statistical redundancy. Although the clinical diagnosis 
of liver cirrhosis has been conventionally made based on 
ultrasonography and laboratory tests, a recent study proved 
that LS value can be more accurate in detecting compensated 
liver cirrhosis than can clinical criteria in terms of assessing 
the risk of HCC development.13 Furthermore, in contrast to 
TE, which has shown high reproducibility, the subjectivity 
of ultrasonography can be another problem in diagnosing 
liver cirrhosis clinically.27 Lastly, the risk of HCC recurrence 
was significantly higher in patients with .13 kPa and liver 
cirrhosis (n=59 [53.2%]) than that in patients with #13 kPa 
and liver cirrhosis (n=16 [14.4%]) in our study (P,0.001 
by logrank test). All these indicate that TE has an additional 
role, as one of predictor for HCC recurrence, even among 
patients with liver cirrhosis.
Repeated studies revealed that antiviral treatment can 
reduce the recurrence of HBV- or HCV-related HCC after 
RFA.28,29 However, we could not found any significant cor-
relation between antiviral therapy and recurrence among 
HBV- and HCV-related HCC patients. Because the small 
sample size of patients with each HCC etiology can be related 
to the false negative results, further large study are required 
to clarify this issue.
LS values, together with total bilirubin,15 were also inde-
pendent predictive factors for OS after RFA, which means 
that the physical hardness of liver as assessed by using TE 
and functional liver reserve can independently and simul-
taneously influence the mortality after RFA. However, in 
contrast to previous studies,15,30 variables related to tumor 
burden were not identified as independent predictors of OS 
in our study. This phenomenon can be explained in several 
ways, such as the low proportion of subjects who died from 
HCC progression (6 of 14 [43%]) and the relatively low 
tumor burden in our cohort.
There are still several unresolved issues in our study. 
First, the criteria used to classify local recurrence and de 
novo recurrence are somewhat ambiguous.15 Among the de 
novo recurrence, it is practically impossible to distinguish 
intrahepatic metastasis from original tumor or a newly devel-
oped tumor in the diseased liver.8 Also, because we excluded 
the patients who experienced only local tumor progression, 
our results were subject to a selection bias, and the influ-
ence of some risk factors might have been underestimated. 
Third, in previous studies, HBV-related HCC developed 
in noncirrhotic livers, whereas HCV-related HCC occurs 
mostly in the presence of cirrhosis.31 Indeed, HBV-related 
HCC patients had significantly lower mean LS values than 
did HCV-related HCC patients (18.6 vs 29.5 kPa). However, 
the etiology of HCC only tended to influence the risk of 
recurrence (P=0.093) (Table 4). Although the exact reason 
for this result is not clear, the small sample size of patients 
with each etiology might have been insufficient to make a 
statistical difference. Finally, our short follow-up duration 
after RFA (median 22.4 months) does not seem sufficient 
to assess the influence of LS values on OS. Thus, large-
scale prospective studies with consecutive enrollment and 
long-term follow-up duration could resolve the pitfalls of 
our study.
In conclusion, patients with a previous treatment history 
and higher LS values, .13.0 kPa, were at a significantly 
greater risk for de novo recurrence after RFA. In addition, 
patients with LS values .13.0 kPa, together with higher total 
bilirubin, experienced significantly decreased OS after RFA. 
Although our study indicates that LS measurement by using 
TE is useful for predicting de novo recurrence of HCC in the 
remnant liver as well as survival after RFA, external valida-
tion of our results in future large-scale prospective studies 
can expand the clinical implications of TE in a longitudinal 
perspective.
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